Human Milk Oligosaccharides and Infant Gut Health: What Parents Should Know

Human milk oligosaccharides, or HMOs, are a type of carbohydrate found in breast milk.

They are the third most common solid part of breast milk, after lactose and fat.

A baby's own body cannot break down most HMOs.

Instead, HMOs travel to the large intestine, where they feed certain gut bacteria.

This makes HMOs a type of prebiotic, a food source for helpful microbes rather than for the baby directly.

There are more than 150 different HMOs identified in breast milk, each with a slightly different structure.

The exact mix of HMOs in a mother's milk can change over time and differs from person to person.

The first months of life are a critical window for building the immune system.

During this time, the gut microbiome, the community of bacteria living in the intestines, helps teach immune cells how to respond to germs, food, and the body's own tissues.

Babies with lower levels of HMO-loving bacteria, especially a strain called Bifidobacterium infantis, appear to have a higher risk of immune-related problems later on.^[1]

This includes conditions linked to an overactive or poorly balanced immune response, such as allergies and asthma.

Because of this link, researchers have been studying whether adding HMOs and specific bacteria to infant formula can help formula-fed babies develop immune patterns closer to those of breastfed babies.

HMOs work mainly by feeding good bacteria, not by acting on the body directly.

One key bacterium that thrives on HMOs is Bifidobacterium infantis.

When this bacterium breaks down HMOs, it produces byproducts that can talk to the immune system.

A large clinical and preclinical study found that a synbiotic, a combination of live bacteria and the food that feeds them, made from B. infantis and a blend of six different HMOs plus another bacterium, Bifidobacterium lactis, changed the gut microbiome of formula-fed infants.^[1]

This synbiotic also changed patterns of immune cells in the blood.^[1]

Specifically, it reduced a lasting Th2 immune bias.^[1]

Th2 is a branch of the immune system that, when overactive for too long, is tied to allergic and asthma-type responses.

The synbiotic-fed infants showed immune patterns that looked more like those of breastfed infants.^[1]

In animal models, the same synbiotic reduced the severity of lower respiratory tract infections and calmed down harmful type-2 immune responses.^[1]

These protective effects lasted into adulthood in the animal models, suggesting a lasting imprint from early feeding.^[1]

Researchers also found a specific molecule, 12-HHT, that rose in the blood after synbiotic feeding and was linked to better infection outcomes.^[1]

When this molecule was given on its own, it copied some of the protective effects, pointing to one possible pathway behind the benefit.^[1]

Much of the strongest evidence for HMOs comes from comparing breastfed and formula-fed infants.

Breast milk naturally contains a rich and diverse mix of HMOs, along with live bacteria, antibodies, and other immune-supporting compounds.

Formula has historically lacked this same complexity, though newer formulas now add specific HMOs to try to close the gap.

The 2026 study combining clinical data from infants with animal models is one of the more detailed looks at how an HMO-bacteria combination might shape immune development over time.^[1]

It is important to note that this research was funded by a formula manufacturer, and several authors are employees of that company or hold related patents.^[1]

This kind of industry involvement is common in infant nutrition research, but it means results should be viewed alongside independent studies as they emerge.

Overall, the direction of the evidence supports the idea that HMOs are not just filler ingredients in breast milk, but active shapers of early immune health.

For most families, there is no single required action, since HMO research is still developing.

A few practical points can help guide decisions.

• Breastfeeding, when possible and desired, remains the most natural way to provide a full, diverse mix of HMOs.
• If using formula, look for products that list added HMOs, such as 2'-fucosyllactose, on the label.
• Talk with a pediatrician before switching formulas, especially for infants with health conditions or feeding difficulties.
• Remember that gut bacteria like Bifidobacterium species can also be supported later in life through fiber-rich foods once a baby starts solids.
• Avoid assuming that any single supplement or formula additive fully replaces the complexity of breast milk.

Introducing fiber-containing foods later in infancy, such as oats, fruits, and vegetables, can continue to support a healthy gut microbiome as children grow.

Formula-fed infants are the most direct focus of this research, since they may not get the same natural HMO exposure as breastfed babies.

Infants with a family history of allergies, asthma, or other immune-related conditions may be of particular interest for future studies.

Infants who are more prone to respiratory infections could also be a group where these findings matter most, based on the reduced infection severity seen in animal models.^[1]

Researchers themselves may also benefit, as the discovery of molecules like 12-HHT opens new paths for understanding how gut bacteria influence distant organs like the lungs.^[1]

Put this to work in your own food log. Track it free with Ration →